In August, the FDA granted priority review to an experimental drug to treat a form of blood cancer called mantle cell lymphoma. The compound, acalabrutinib, performed well in its early trials — well enough that AstraZeneca paid $4 billion in 2016 for a majority stake in Acerta, which makes the therapy. But in an unusual step, Acerta this month admitted that at least one of those early studies — not in humans — contained faked data. According to the company, a researcher for the drug maker falsified results in a 2015 abstract, published in Cancer Research, on the use of acalabrutinib to treat pancreatic cancer. Acerta, which has parted ways with the employee, insists the fraud does not undermine the potential or safety of its product. And the journal has retracted the tainted study, which had been presented at a big cancer meeting. Meanwhile, trials of the drug continue.
A large-scale study throws cold water on a popular idea.Continue reading »
It’s the number-one lender of words to other languages--but not everyone wants to borrow them.Continue reading »
The parents of Ben Pollack, a nonverbal teenager, want him to carry an audio recorder during the school day to ensure that he is not mistreated.Continue reading »
The knowledge, tools, and seeds we’ll want if disaster strikes.Continue reading »
The campus-bred identitarian left is leaving its mark on society.Continue reading »
A collection of Audubon’s early drawings shows it took the great ornithologist time to develop his style.Continue reading »